歌禮製藥(01672.HK)FASN抑制劑II期臨床試驗之中國隊列取得良好頂線數據
歌禮製藥(01672.HK)旗下全資附屬公司甘萊製藥與Sagimet Biosciences聯合宣佈,脂肪酸合成(酉每)(Fatty Acid Synthase,簡稱FASN)抑制劑ASC40(國外代號為TVB-2640)在隨機、安慰劑對照II期臨床試驗的中國隊列中取得良好頂線數據(topline results)。口服、每日一次的ASC40有望成為治療非酒精性脂肪性肝炎(NASH)的藥物。
初步數據顯示,ASC40顯著降低肝臟脂肪含量(該試驗的主要療效終點),應答率達50%。受試者的丙氨酸氨基轉移(酉每)(ALT,一種與炎症相關的肝臟(酉每))也表現出顯著改善。中國隊列數據與2020年11月發表於美國肝病研究協會(AASLD)肝病會議上的美國隊列數據結果一致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.